XDH and metabolic dysfunction-associated steatotic liver disease: Given the fact that allopurinol is a purine analog, febuxostat is a non-purine xanthine oxidase inhibitor, and allopurinol has a broader effect among purine metabolism [37,38], active purine metabolism per se or other by-products of purine metabolic activity might have affected the cardiovascular risk in NAFLD patients.